other material
confidence high
sentiment negative
materiality 0.75
20/20 Biolabs enters standstill with Streeterville; receives Nasdaq bid price deficiency notice
20/20 Biolabs, Inc.
- Standstill agreement with Streeterville: 120-day forbearance on conversion of Series E preferred unless stock price >10% above Nasdaq Minimum Price.
- Nasdaq notified company of non-compliance with $1.00 bid price rule for 30 consecutive business days through July 16, 2026.
- Company has 180 calendar days (until January 13, 2027) to regain compliance by closing bid price at $1.00 for 10 consecutive business days.
- If not compliant by Jan 13, 2027, may qualify for a second 180-day period if it meets other listing standards.
- Company intends to monitor bid price and consider available options to cure the deficiency.